Alan L. Wagner
About
In The Last Decade
Alan L. Wagner
23 papers receiving 167 citations
Peers
Comparison fields: 5 of 45
- Ophthalmology 148
- Radiology, Nuclear Medicine and Imaging 85
- Molecular Biology 20
- Epidemiology 15
- Neurology 9
Countries citing papers authored by Alan L. Wagner
This map shows the geographic impact of Alan L. Wagner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan L. Wagner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan L. Wagner more than expected).
Fields of papers citing papers by Alan L. Wagner
This network shows the impact of papers produced by Alan L. Wagner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan L. Wagner. The network helps show where Alan L. Wagner may publish in the future.
Co-authorship network of co-authors of Alan L. Wagner
This figure shows the co-authorship network connecting the top 25 collaborators of Alan L. Wagner. A scholar is included among the top collaborators of Alan L. Wagner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan L. Wagner. Alan L. Wagner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 5 | |
| 2 | 0 | |
| 3 | 12 | |
| 4 | Real-world analysis of brolucizumab in neovascular AMD | 1 |
| 5 | Psychological Stress during COVID-19 and Central Serous Chorioretinopathy (CSCR) | 1 |
| 6 | Cost Efficacy and Challenges of Real-world Brolucizumab use for Neovascular AMD | 1 |
| 7 | High-dose, High-frequency intravitreal aflibercept for Wet AMD | 1 |
| 8 | 9 | |
| 9 | 0 | |
| 10 | 4 | |
| 11 | 26 | |
| 12 | 3 | |
| 13 | 2 | |
| 14 | 31 | |
| 15 | 2 | |
| 16 | 10 | |
| 17 | Permeability of the blood-retinal barrier and the blood-aqueous barrier in type I diabetes without diabetic retinopathy: simultaneous evaluation with fluorophotometry. | 9 |
| 18 | 8 | |
| 19 | 6 | |
| 20 | 2 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.